Nitric oxide mimetics - Cellegy

Drug Profile

Nitric oxide mimetics - Cellegy

Latest Information Update: 07 Aug 2007

Price : $50

At a glance

  • Originator Cellegy Pharmaceuticals
  • Class Antiacnes; Antiandrogens; Antibacterials; Antifungals; Antihypertensives; Antivirals; Free radicals; Macromolecular substances; Nitrogen oxides; Non-opioid analgesics; Small molecules; Vasodilators
  • Mechanism of Action Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Prostate cancer

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 31 Dec 2006 Discontinued - Phase-I for Prostate cancer in USA (unspecified route)
  • 28 Nov 2005 Cellegy and New Harbour Corporation have entered into a licensig agreement for nitric oxide donor therapy in China for the treatment of anal disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top